Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

about

Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase.

P2860

Q47105617-0A1C0959-2229-4025-BFC9-AA8C06DEA58B Q54976582-F4DA804E-9A95-4187-8ADB-6DCB90E256AB

P2860

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

Item

http://www.wikidata.org/entity/Q47777234

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@en

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@nl

type

Item

label

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@en

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@nl

prefLabel

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@en

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@nl

P1476

Molecular and clinical feature ...... kinase inhibitors: ceritinib.

@en

P2093

Chiara Catania

http://www.w3.org/2001/XMLSchema#string

Fabio Conforti

http://www.w3.org/2001/XMLSchema#string

Tommaso De Pas

http://www.w3.org/2001/XMLSchema#string

P2860

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

Crizotinib resistance: implications for therapeutic strategies

The role of the ALK receptor in cancer biology

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

P304

2629-2644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0262

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura Pala

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28891712

http://www.w3.org/2001/XMLSchema#string

P921

ceritinib

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

about

P2860

P2860

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921